Developing Novel Personalized Cancer Vaccines and Bi-Functional Antibody Drug Conjugates (ADCs)

We are a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Through our leading IFx technology, we are developing personalized cancer vaccines to overcome tumor resistance to immunotherapies like checkpoint inhibitors. We plan to initiate a Phase 3 Accelerated Approval trial for an aggressive form of skin cancer called Merkel Cell Carcinoma in 2024 and to advance our 2nd cancer vaccine for potential use in blood related cancers like aggressive lymphoma. Using our first-in-class Delta technology we are developing bi-functional antibody drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells (MDSCs) to modulate their immunosuppressive effects on the tumor microenvironment. Our technologies are designed to overcome primary and acquired resistance to checkpoint inhibitors or cellular therapies in the treatment of cancer.

Overcoming Two Major Obstacles that Limit the Effectiveness of Cancer Immunotherapies

We are advancing two proprietary technologies to overcome:


  • Primary or Innate Resistance to checkpoint inhibitors or cellular therapies related to tumor intrinsic factors such as low mutational burden or low neoantigen load associated with insufficient tumor immunogenicity that allows the tumor to escape immune recognition and attack.
  • Secondary or acquired resistance to immunotherapies, resulting from extrinsic factors that result in highly immunosuppressive tumor microenvironment, the tissue in which the tumor lives that causes immunotherapies like checkpoint inhibitors to stop working.

Advancing Two Innovative Platform Technologies

IMMUNE FX™ (IFx™): Personalized Cancer Vaccines Harnessing the Power of the Innate Immune Response

Our IFx technology is designed to “trick” the body’s immune system to attack tumor cells by making tumor cells look like bacteria and harness the power of innate immunity by leveraging natural mechanisms conserved throughout evolution to recognize threats from foreign pathogens like bacteria or viruses.

Bi-Functional Antibody Drug Conjugates (ADCs)

Leveraging our proprietary Delta receptor technology we are developing first-in-class bi-functional antibody drug conjugates (ADCs) that target Myeloid Derived Suppressor Cells (MDSCs) to inhibit their immune suppressing effects of MDSCs on the tumor microenvironment. This may prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies, allowing them to continue working.



Your tooltip content goes here


Your tooltip content goes here


Your tooltip content goes here

Sign Up For Alerts!